- Research article
- Open Access
Murine CD4+CD25- cells activated in vitro with PMA/ionomycin and anti-CD3 acquire regulatory function and ameliorate experimental colitis in vivo
BMC Gastroenterology volume 12, Article number: 172 (2012)
Induced regulatory T (iTreg) lymphocytes show promise for application in the treatment of allergic, autoimmune and inflammatory disorders. iTreg cells demonstrate advantages over natural Treg (nTreg) cells in terms of increased number of starting population and greater potential to proliferate. Different activation methods to generate iTreg cells result in iTreg cells that are heterogeneous in phenotype and mechanisms of suppression. Therefore it is of interest to explore new techniques to generate iTreg cells and to determine their physiological relevance.
Using phorbol myristate acetate (PMA)/ionomycin and anti-CD3 activation of CD4+CD25- cells we generated in vitro functional CD4+CD25+ iTreg (TregPMA) cells. Functionality of the generated TregPMA cells was tested in vivo in a mouse model of inflammatory bowel disease (IBD) - CD45RB transfer colitis model.
TregPMA cells expressed regulatory markers and proved to ameliorate the disease phenotype in murine CD45RB transfer colitis model. The body weight loss and disease activity scores for TregPMA treated mice were reduced when compared to diseased control group. Histological assessment of colon sections confirmed amelioration of the disease phenotype. Additionally, cytokine analysis showed decreased levels of proinflammatory colonic and plasma IL-6, colonic IL-1 β and higher levels of colonic IL-17 when compared to diseased control group.
This study identifies a new method to generate in vitro iTreg cells (TregPMA cells) which physiological efficacy has been demonstrated in vivo.
T regulatory (Treg) lymphocytes are a cellular component of the immune system responsible for suppressing immune responses of effector cells. As a result of their ability to control immune responses and to sustain systemic immune balance, they have the potential to prevent allergic, autoimmune and inflammatory disorders [1–10] as well as to be an adjuvant therapy for chronic and acute graft versus host disease .
The safety profile of Treg cells has been established in phase I clinical trials [11, 12] demonstrating that Treg cells are a suitable candidate for therapeutic purposes. However a major limitation to the clinical use of natural Treg (nTreg) cells is their low availability as they represent only a small percentage of the peripheral circulating CD4+ T cell population. In order to overcome this issue, several groups have developed methods to expand nTreg cells in vitro when keeping their functionality. Generally the technologies are complex, time-consuming and the plasticity of nTreg cell lineage in artificial environment during ex vivo expansion can lead to loss of their suppressive activity . Furthermore their stage of differentiation makes their expansion in vitro a difficult process .
In vitro induced T regulatory (iTreg) cells represent a good alternative to nTreg cells since they have been reported to have similar functionality in in vivo setup. Additionally iTreg cells show advantages over nTreg cells in terms of increased number of starting population and greater potential to proliferate . Therefore it is of importance to investigate and explore new approaches to generate iTreg cells.
Based on the activating and stimulating properties of phorbol myristate acetate (PMA)/ionomycin and anti-CD3 on T cells [16, 17] we developed a new method to generate iTreg cells in vitro, which we refer to as ‘TregPMA’ cells. The functionality of the TregPMA cells was assessed in vivo in a mouse model of experimental colitis.
BALB/C and C.B.-17 SCID mice (8–10 weeks) were obtained from Harlan and maintained in specific pathogen-free conditions. Mouse experiments were approved by the local animal welfare committee (University of Amsterdam).
Generation of regulatory T lymphocytes (Treg PMA cells)
Splenocytes were isolated from BALB/C mice. CD4+ CD25- T cells were isolated from splenocytes by means of negative selection using the mouse “CD4+ T Cell Isolation Kit” followed by “CD25 MicroBead Kit” (Miltenyi Biotec). Cells were seeded at day 0 at 1x105/well into anti-CD3e (0.5 μg/well, clone 145-2C11, eBioscience) coated 96-well flat bottom plates (Costar) and cultured in X-VIVO 15 medium (Lonza) at 37°C in a 5% CO2 incubator. On day 1, cells were activated with PMA (10 ng/ml) and ionomycin (250 ng/ml) and at day 2, 3 and 4 supplemented with 20 U/well of IL-2 (eBioscience). On day 5, prior to use, cells were harvested and treated with “Dead Cell Removal Kit” (Miltenyi Biotec).
Flow cytometry analysis
Cells were analyzed using flow cytometry (FACSCalibur, BD Biosciences). For Treg cell staining the mouse “Regulatory T cell Staining Kit” was used which consisted of anti-mouse CD4 FITC (clone RM4-5), anti-mouse CD25 APC (clone PC61.5) and anti-mouse/rat Foxp3 PE (clone FJK16). Additional monoclonal anti-mouse flow cytometry antibodies used in this study were as follows: anti-mouse CD152 (CTLA-4) APC (clone UC10-4B9), anti-mouse GARP PE (clone YGIC86), anti-mouse/rat CD278 (ICOS) FITC (clone C398.4A) and anti-mouse CD134 (OX-40) APC (clone OX86). All antibodies were obtained from eBioscience.
Induction of CD45RB transfer colitis model and treatment with TregPMA cells
Chronic colitis was induced in C.B.-17 SCID mice by intraperitoneal (IP) injection of CD45RBhigh cells (4x 105) isolated from normal BALB/C mice splenocytes (positive control group). Mice that received CD45RBhigh cells in combination with CD45RBlow cells (2x105) were protected from disease development (negative control group). The treatment group received CD45RBhigh cells in combination with in vitro generated TregPMA cells (TregPMA cell treated group). The amount of TregPMA cells injected per mouse was 1.2x106.
Monitoring development of colitis
The primary read-out to assess the development of colitis was the body weight loss. Mice were weighed three times a week. Body weight loss was determined by percentage of weight loss from base line body weight.
After sacrifice, colon was excised and longitudinally divided into 2 parts both of which were rolled up: one was used for preparation of paraffin embedded samples while the other was snap frozen in liquid nitrogen. Disease activity index (DAI) was calculated by combining the scores applied to weight loss (0: <1%; 1: 1-5%; 2: 5-10%; 3: 10-15%; 4: >15%), stool consistency at sacrifice (0: normal; 1: loose droppings; 2: loose stools, colon filled with feces; 3: loose stool, feces only near caecum, 4: empty bowel) and rectal bleeding (0: negative; 2: positive; 3: gross bleeding) divided by three.
The half divided colon tissue was fixed in 4% paraformaldehyde and embedded in paraffin. The colon tissue was cut in 5 μm sections and stained with hematoxylin and eosin for histological scoring. An experienced pathologist blinded to experiment inspected microscopically all sections and graded them on a scale 0 to 4 looking at: mononuclear and polymorphonuclear infiltrate, goblet cell depletion, crypt loss, epithelial hyperplasia, presence of ulcerations and manifestations of crypt abscesses.
Frozen colon tissue was crushed with the use of CryoPrep™ System (Covaris) and resuspended in ice-cold PBS (pH 7.2) containing complete protease inhibitor (Roche). Homogenates were then centrifuged at 15000 x g for 5 min at 4°C and the supernatants were stored at −80°C until the cytokine assay. Prior to cytokine analysis total concentration of the protein in supernatants was determined with the use of Bradford assay (Biorad). Colonic tissue and plasma levels of IL-1β, IL-6, IL-10, IL-17 and TNF-α were analyzed using a mouse cytokine magnetic bead-based multiplex assay (Biorad) according to the manufacturer’s instructions. Additionally TGF-β levels were analyzed with Bio-Plex Pro TGF-β assay (Biorad) according to manufacturer’s instructions.
Data were analyzed statistically and graphed using Prism 5.0 (GraphPad Software). Changes in mice weekly body weight, body weight at sacrifice, disease activity index (DAI), histological score and cytokine levels are shown as mean ± standard deviation (SD) and analyzed by one-way ANOVA, followed by Bonferroni’s Multiple Comparison Test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
CD4+CD25-T cells acquire a regulatory T cell phenotype through PMA/ionomycin/anti-CD3 mediated activation
In order to generate regulatory T cells, CD4+CD25- cells from BALB/C mice were activated overnight on 96-well plate coated with anti-CD3. Subsequently PMA/ionomycin and IL-2 were added to the cell culture. After 5 days in culture, the cells were analyzed for their phenotype by flow cytometry. Between 85.26% and 91.85% of the cultured cells were shown to up-regulate and co-express the CD4 and CD25 markers (mean 91.4 ± 5.9%, n = 3, see: Figure 1A, C). The absence of PMA/ionomycin activation step on CD4+CD25- cells resulted in significant decrease in cell viability (data not shown) which confirms the necessity of additional activation with PMA/ionomycin.
Additionally, we analyzed the expression of Foxp3, CTLA-4, GARP, ICOS and OX-40 markers which are known to be associated with a T regulatory cell phenotype and function [18–22]. All tested markers were found to be up-regulated in ~30% of the CD4+CD25+ T cells after activation (a representative result is shown in Figure 1D, Figure 2A, B, C, D).
Similarly to previously reported data with iTreg cells generated in vitro, the cellular level of Foxp3 expression in the cells activated with PMA/ionomycin/anti-CD3 appears to be low (see: Figure 1B, D).
We will refer to the cells activated with PMA/ionomycin/anti-CD3 activation (iTreg cell population) as ‘TregPMA’ cells.
TregPMA cells ameliorate the disease phenotype in a colitis transfer mouse model
IBD was induced in C.B-17 SCID mice by transfer of CD45RBhigh cell population from BALB/C mice (positive control group) and was prevented by co-transfer of CD45RBlow cell population (negative control group) [24–27].
The read-out parameters of the development and progression of the colitis in the transfer mouse model are body weight loss and inflammation of the intestinal tissue.
The positive control group developed colitis and presented a relative decrease of initial body weight 86.88 ± 5.06% (n = 9) at sacrifice which was significantly lower than the negative control that reached 110 ± 3.29% (n = 10) of the initial body weight. The TregPMA cell treatment (injection of TregPMA cells together with CD45RBhigh cells) reduced significantly the body weight loss to 99.18 ± 7.17% (n = 10) as compared to the positive control group (Figure 3A, B).
The Disease Activity Index (DAI), which is an indicator of colonic inflammation, reflecting weight loss, stool consistency and presence of rectal bleeding was determined at sacrifice. The DAI was significantly lower in mice treated with TregPMA cells (1.18 ± 0.55) when compared to the positive control group (2.04 ± 0.35), confirming the amelioration of the disease phenotype (Figure 3C).
Intestinal inflammation was further determined by histopathological analysis of colon tissue post mortem which includes evaluation of mononuclear and polymorphonuclear cell infiltrate, goblet cell depletion, loss of crypts, epithelial hyperplasia and manifestations of ulcerations and abscesses [24–27].
A significant reduction of inflammation was observed in the colon tissue of the TregPMA cell treated mice when compared to the positive control group (Figure 3D). The spread of intestinal inflammation was less extensive and no ulcerations were observed in the TregPMA cell group (Figure 4B) which was similar to the negative control group (Figure 4A) while in the diseased control group they were commonly present (Figure 4C).
Proinflammatory cytokine production in colon and in plasma of TregPMA cell treated mice is reduced
We next examined the influence of TregPMA cell treatment on the production of pro-inflammatory cytokines IL-6, IL-1β and TNF-α that have been previously described to be increased in CD45RB transfer colitis mouse model [28, 29]. The level of IL-10 and TGF-β that have been shown to have a regulatory effect in experimental colitis were also analyzed [30, 31]. Additionally the level of IL-17 cytokine that have been described to have both pro- and anti-inflammatory effect in IBD was measured [30, 32–35].
The level of IL-6 was found to be decreased in TregPMA cell treated group in both colon homogenates and plasma at the day of sacrifice when compared to the positive control group (Figure 5A, D). IL-1β level was also found to be reduced after TregPMA cell treatment in colon homogenates but this decrease was not reflected in plasma (Figure 5B, E).
Elevated levels of IL-17 were found in colon tissue homogenates of TregPMA cell treated mice as well as in positive control group. However, the TregPMA cell treated group had higher level of colonic IL-17 than the positive control (Figure 5C). No significant difference between groups was observed in the levels of IL-17 expression in plasma (Figure 5F).
TNF-α, IL-10 and TGF-β levels in both colon homogenates and plasma showed no significant differences between groups (data not shown).
In this article we describe the generation of iTreg cells (TregPMA cells) in vitro from CD4+CD25- cells by PMA/ionomycin/anti-CD3 activation based method. Several other groups have explored different strategies to generate iTreg from naive T cells in vitro, including use of TGF-β, all-trans-retinoic acid and the recently discovered regulatory cytokine IL-35 [36, 37]. However, all these methods are more or less impeded with their own limitations . Therefore, there is need for improvement in this field and our group designed and explored a new method of in vitro iTreg cells (TregPMA) generation which we report in this manuscript.
Mechanistically, PMA/ionomycin provides a potent stimulation allowing us to bypass the T cell receptor activation essential for Treg cell development and it prevents the emergence of CD4-CD8+ cells in the culture . PMA activates protein kinase C  while ionomycin is a Ca2+ mobilizing agent . This combination has been shown to up-regulate CD25 on T lymphocytes  and a high CD25 expression is a marker of the Treg cell phenotype . Additionally, it was demonstrated that Ca2+ signaling is required for the development and function of Treg cells [41, 42]. Therefore we expected that raising the intracellular levels of Ca2+ in naive T cells using ionomycin would have a synergistic effect with PMA in starting a regulatory developmental program in CD4+CD25- cells. Additionally a low dose of IL-2 was used in cell culture since IL-2 is important for Treg cell homeostasis and maintaining their suppressive survival program  while anti-CD3 which is also present in the cell culture has been shown to maintain and expand Treg cells , however use of only anti-CD3 and IL-2 for in vitro CD4+CD25- cell stimulation resulted in low cell viability and poor regulatory markers expression which indicates that additional stimulation with PMA/ionomycin is needed.
The TregPMA cells up-regulate CD25, and ~30% of the CD4+CD25+ T cells up-regulate CTLA-4, GARP, ICOS, OX-40 and Foxp3 which are important markers associated with regulatory cell phenotype and function [18–22, 45, 46]. Interestingly, the level of Foxp3 expression in TregPMA cells is quite low. Although Foxp3 expression is considered to be a main characteristic of Treg cells, Treg cells are recognized to be a heterogeneous cell population. Especially, it has been reported that CD4+CD25+ Foxp3- cell population also can present regulatory function in vitro and in vivo.
The functionality of the TregPMA cells has been demonstrated in vivo by their potential to ameliorate the disease phenotype in a CD45RB transfer colitis mouse model. It cannot be fully excluded that the amelioration of the disease phenotype observed in the group of mice treated with the TregPMA cells does not partially involve cell types, other than regulatory, present in the cell suspension injected. Indeed, high numbers of CD45RBhigh cells (6x106/mouse) have been shown to reduce the severity of the disease in a mouse model of colitis . However, in our study, the total number of cells injected (1,2x106/mouse) was significantly lower and the amelioration of the severity of the disease was observed in all of the treated animals (n = 10) against 3 out of 5 in the mentioned study. All together, these data suggest that the observed protective effect is mostly related to TregPMA cells.
The disease amelioration after TregPMA treatment was accompanied by a decrease of the pro-inflammatory IL-1 β levels in the colon tissue which reflect the severity of experimental colitis . Such a decrease in IL-1β was previously reported by Hirano and Kudo after treatment of CD45RB transfer colitis mouse model with both dexamethasone and anti-tumor necrosis factor-α (anti-TNF-α).
IL-1β stimulates the production of the pro-inflammatory cytokine IL-6  which has been described to be up-regulated in mouse model of IBD  and in human ulcerative colitis or Crohn’s disease patients . Simultaneously with the decrease of IL-1β in our study, IL-6 levels were found to be reduced in both colonic homogenates and plasma samples after treatment with TregPMA cells.
The concentration of IL-17 was found to be more elevated in colon homogenates of TregPMA cell treated mice than in the positive control group. Although the role of this cytokine in the initiation or pathogenesis of IBD is controversial, a protective function of IL-17 in the gut of CD45RB transfer colitis model has been previously noted [30, 33, 51]. Several groups have reported that both IL-17−/− CD45RBhigh and IL-17R−/− CD45RBhigh cells induce a more aggressive disease phenotype than wild type CD45RBhigh cells [30, 51]. Accordingly, our results show that an increased IL-17 level also correlated with less severe intestinal inflammation and lack of ulcerations.
IL-10 and TGF-β cytokine level in both mouse plasma and colon homogenates show no significant differences between experimental groups at the time of experiment termination (week 7). However, it does not exclude the possible influence of those cytokines on prevention of the colitis induction at earlier time point.
The cells that have been found mostly responsible for pathogenesis of CD45RB transfer model of IBD are Th1 cells. Recently it has been shown that IL-17 blocks the Th1 cell development in vivo via IL-17R on naive CD4+ T cells [30, 51]. In the TregPMA cell treated group we also observe elevated level of IL-17 which correlates with disease amelioration. IL-17 can be produced by many types of cells among which are also T regulatory cells . Therefore we are hypothesizing that in vivo disease amelioration by TregPMA cells is IL-17 mediated. As follow-up to this study, physiological relevance of TregPMA cells and their exact molecular mechanism of action needs to be determined.
Induced regulatory T cells are promising tools for therapeutic applications in IBD  as well as in other autoimmune disorders and are of great scientific interest. Many techniques to generate inducible Treg cells from naive T cells have been developed and described [8, 36, 37, 54, 55]. Different activation methods to generate iTreg cells result in iTreg cells that are heterogeneous in phenotype. The in vitro PMA/ionomycin/anti-CD3 activation of CD4+CD25- T cells has proven to generate functional iTreg cells (TregPMA cells) but the in vivo physiological relevance of TregPMA cell signaling needs to be further investigated.
Phorbol myristate acetate
Induced regulatory T cells
Natural regulatory T cells
Inflammatory bowel diseases
Severe combined immunodeficiency
Disease activity index
Tumor necrosis factor- alpha.
DiPaolo RJ, Glass DD, Bijwaard KE, Shevach EM: CD4 + CD25+ T cells prevent the development of organ-specific autoimmune disease by inhibiting the differentiation of autoreactive effector T cells. J Immunol. 2005, 175: 7135-7142.
Huter EN, Stummvoll GH, DiPaolo RJ, Glass DD, Shevach EM: Cutting edge: antigen-specific TGF beta-induced regulatory T cells suppress Th17-mediated autoimmune disease. J Immunol. 2008, 181: 8209-8213.
Kohm AP, Carpentier PA, Anger HA, Miller SD: Cutting edge: CD4 + CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J Immunol. 2002, 169: 4712-4716.
Ly D, Mi QS, Hussain S, Delovitch TL: Protection from type 1 diabetes by invariant NK T cells requires the activity of CD4 + CD25+ regulatory T cells. J Immunol. 2006, 177: 3695-3704.
Manirarora JN, Kosiewicz MM, Parnell SA, Alard P: APC activation restores functional CD4(+)CD25(+) regulatory T cells in NOD mice that can prevent diabetes development. PLoS One. 2008, 3: e3739-10.1371/journal.pone.0003739.
Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995, 155: 1151-1164.
Scalapino KJ, Tang Q, Bluestone JA, Bonyhadi ML, Daikh DI: Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol. 2006, 177: 1451-1459.
Wang S, Xu H, Wang Y, Ma J, Mao C, Shao Q, et al: Regulatory T cells induced by rAAV carrying the forkhead box P3 gene prevent autoimmune thyroiditis in mice. Int J Mol Med. 2006, 18: 1193-1199.
Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, et al: A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997, 389: 737-742. 10.1038/39614.
Mottet C, Uhlig HH, Powrie F: Cutting edge: cure of colitis by CD4 + CD25+ regulatory T cells. J Immunol. 2003, 170: 3939-3943.
Trzonkowski P, Bieniaszewska M, Juscinska J, Dobyszuk A, Krzystyniak A, Marek N, et al: First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4 + CD25 + CD127- T regulatory cells. Clin Immunol. 2009, 133: 22-26. 10.1016/j.clim.2009.06.001.
Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, et al: Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011, 117: 1061-1070. 10.1182/blood-2010-07-293795.
Marek N, Bieniaszewska M, Krzystyniak A, Juscinska J, Mysliwska J, Witkowski P, et al: The time is crucial for exvivo expansion of T regulatory cells for therapy. Cell Transplant. 2011, in press
Taams LS, Vukmanovic-Stejic M, Smith J, Dunne PJ, Fletcher JM, Plunkett FJ, et al: Antigen-specific T cell suppression by human CD4 + CD25+ regulatory T cells. Eur J Immunol. 2002, 32: 1621-1630. 10.1002/1521-4141(200206)32:6<1621::AID-IMMU1621>3.0.CO;2-Q.
Hippen KL, Merkel SC, Schirm DK, Nelson C, Tennis NC, Riley JL, et al: Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease. Am J Transplant. 2011, 11: 1148-1157. 10.1111/j.1600-6143.2011.03558.x.
Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R, et al: Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol. 2007, 19: 345-354. 10.1093/intimm/dxm014.
Takahama Y, Nakauchi H: Phorbol ester and calcium ionophore can replace TCR signals that induce positive selection of CD4 T cells. J Immunol. 1996, 157: 1508-1513.
Wing K, Yamaguchi T, Sakaguchi S: Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation. Trends Immunol. 2011, 32: 428-433. 10.1016/j.it.2011.06.002.
Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al: CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008, 322: 271-275. 10.1126/science.1160062.
Wang R, Wan Q, Kozhaya L, Fujii H, Unutmaz D: Identification of a regulatory T cell specific cell surface molecule that mediates suppressive signals and induces Foxp3 expression. PLoS One. 2008, 3: e2705-10.1371/journal.pone.0002705.
Wang R, Kozhaya L, Mercer F, Khaitan A, Fujii H, Unutmaz D: Expression of GARP selectively identifies activated human FOXP3+ regulatory T cells. Proc Natl Acad Sci U S A. 2009, 106: 13439-13444.
Vocanson M, Rozieres A, Hennino A, Poyet G, Gaillard V, Renaudineau S, et al: Inducible costimulator (ICOS) is a marker for highly suppressive antigen-specific T cells sharing features of TH17/TH1 and regulatory T cells. J Allergy Clin Immunol. 2010, 126: 280-289. 10.1016/j.jaci.2010.05.022.
Niedbala W, Cai B, Liu H, Pitman N, Chang L, Liew FY: Nitric oxide induces CD4 + CD25+ Foxp3- regulatory T cells from CD4 + CD25- T cells via p53, IL-2, and OX40. Proc Natl Acad Sci U S A. 2007, 104: 15478-15483. 10.1073/pnas.0703725104.
Leach MW, Bean AG, Mauze S, Coffman RL, Powrie F: Inflammatory bowel disease in C.B-17 scid mice reconstituted with the CD45RBhigh subset of CD4+ T cells. Am J Pathol. 1996, 148: 1503-1515.
Morrissey PJ, Charrier K, Braddy S, Liggitt D, Watson JD: CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified CD4+ T cells. J Exp Med. 1993, 178: 237-244. 10.1084/jem.178.1.237.
Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL: Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol. 1993, 5: 1461-1471. 10.1093/intimm/5.11.1461.
Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL: Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity. 1994, 1: 553-562. 10.1016/1074-7613(94)90045-0.
Hirano D, Kudo S: Usefulness of CD4 + CD45RBhighCD25- Cell- Transferred SCID Mice for Preclinical Evaluation of Drugs for Inflammatory Bowel Disease. J Pharmacol Sci. 2009, 110: 169-181. 10.1254/jphs.08293FP.
Kanai T, Kawamura T, Dohi T, Makita S, Nemoto Y, Totsuka T, et al: TH1/TH2-mediated colitis induced by adoptive transfer of CD4 + CD45RBhigh T lymphocytes into nude mice. Inflamm Bowel Dis. 2006, 12: 89-99. 10.1097/01.MIB.0000197237.21387.mL.
O'Connor W, Kamanaka M, Booth CJ, Town T, Nakae S, Iwakura Y, et al: A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol. 2009, 10: 603-609. 10.1038/ni.1736.
van Montfrans C, Rodriguez Pena MS, Pronk I, Ten Kate FJ, Te Velde AA, van Deventer SJ: Prevention of colitis by interleukin 10-transduced T lymphocytes in the SCID mice transfer model. Gastroenterology. 2002, 123: 1865-1876. 10.1053/gast.2002.37067.
Kanai T, Mikami Y, Sujino T, Hisamatsu T, Hibi T: RORgammat-dependent IL-17A-producing cells in the pathogenesis of intestinal inflammation. Mucosal Immunol. 2012, 5: 240-247. 10.1038/mi.2012.6.
O'Connor W, Zenewicz LA, Flavell RA: The dual nature of T(H)17 cells: shifting the focus to function. Nat Immunol. 2010, 11: 471-476. 10.1038/ni.1882.
Ogawa A, Andoh A, Araki Y, Bamba T, Fujiyama Y: Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol. 2004, 110: 55-62. 10.1016/j.clim.2003.09.013.
Park YH, Koo SK, Kim Y, Kim HM, Joe IY, Park CS, et al: Effect of in vitro expanded CD4(+)CD25(+)Foxp3(+) regulatory T cell therapy combined with lymphodepletion in murine skin allotransplantation. Clin Immunol. 2010, 135: 43-54. 10.1016/j.clim.2009.11.011.
Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, et al: IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol. 2010, 11: 1093-1101. 10.1038/ni.1952.
Lu L, Zhou X, Wang J, Zheng SG, Horwitz DA: Characterization of protective human CD4CD25 FOXP3 regulatory T cells generated with IL-2. TGF-beta and retinoic acid. PLoS One. 2010, 5: e15150-10.1371/journal.pone.0015150.
Frey MR, Leontieva O, Watters DJ, Black JD: Stimulation of protein kinase C-dependent and -independent signaling pathways by bistratene A in intestinal epithelial cells. Biochem Pharmacol. 2001, 61: 1093-1100. 10.1016/S0006-2952(01)00596-2.
Dadsetan S, Shishkin V, Fomina AF: Intracellular Ca(2+) release triggers translocation of membrane marker FM1-43 from the extracellular leaflet of plasma membrane into endoplasmic reticulum in T lymphocytes. J Biol Chem. 2005, 280: 16377-16382. 10.1074/jbc.M501202200.
Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA: CD4 + CD25high regulatory cells in human peripheral blood. J Immunol. 2001, 167: 1245-1253.
Oh-Hora M, Yamashita M, Hogan PG, Sharma S, Lamperti E, Chung W, et al: Dual functions for the endoplasmic reticulum calcium sensors STIM1 and STIM2 in T cell activation and tolerance. Nat Immunol. 2008, 9: 432-443. 10.1038/ni1574.
Oh-Hora M, Rao A: The calcium/NFAT pathway: role in development and function of regulatory T cells. Microbes Infect. 2009, 11: 612-619. 10.1016/j.micinf.2009.04.008.
Malek TR, Castro I: Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity. 2010, 33: 153-165. 10.1016/j.immuni.2010.08.004.
Nishio J, Feuerer M, Wong J, Mathis D, Benoist C: Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor-specified peripheral niche constraints. J Exp Med. 2010, 207: 1879-1889. 10.1084/jem.20100205.
Chen M, Xiao X, Demirci G, Li XC: OX40 controls islet allograft tolerance in CD154 deficient mice by regulating FOXP3+ Tregs. Transplantation. 2008, 85: 1659-1662. 10.1097/TP.0b013e3181726987.
Griseri T, Asquith M, Thompson C, Powrie F: OX40 is required for regulatory T cell-mediated control of colitis. J Exp Med. 2010, 207: 699-709. 10.1084/jem.20091618.
Barthlott T, Kassiotis G, Stockinger B: T cell regulation as a side effect of homeostasis and competition. J Exp Med. 2003, 197: 451-460. 10.1084/jem.20021387.
Dinarello CA: Interleukin-1. Cytokine Growth Factor Rev. 1997, 8: 253-265. 10.1016/S1359-6101(97)00023-3.
Te Velde AA, de Kort F, Sterrenburg E, Pronk I, Ten Kate FJ, Hommes DW, et al: Comparative analysis of colonic gene expression of three experimental colitis models mimicking inflammatory bowel disease. Inflamm Bowel Dis. 2007, 13: 325-330. 10.1002/ibd.20079.
Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK: Role of cytokines in inflammatory bowel disease. World J Gastroenterol. 2008, 14: 4280-4288. 10.3748/wjg.14.4280.
Yang XO, Chang SH, Park H, Nurieva R, Shah B, Acero L, et al: Regulation of inflammatory responses by IL-17 F. J Exp Med. 2008, 205: 1063-1075. 10.1084/jem.20071978.
Voo KS, Wang YH, Santori FR, Boggiano C, Wang YH, Arima K, et al: Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci U S A. 2009, 106: 4793-4798. 10.1073/pnas.0900408106.
van der Marel S, Majowicz A, van Deventer S, Petry H, Hommes DW, Ferreira V: Gene and cell therapy based treatment strategies for inflammatory bowel diseases. World J Gastrointest Pathophysiol. 2011, 2: 114-122. 10.4291/wjgp.v2.i6.114.
Benson MJ, Pino-Lagos K, Rosemblatt M, Noelle RJ: All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med. 2007, 204: 1765-1774. 10.1084/jem.20070719.
Karlsson F, Robinson-Jackson SA, Gray L, Zhang S, Grisham MB: Ex vivo generation of regulatory T cells: characterization and therapeutic evaluation in a model of chronic colitis. Methods Mol Biol. 2011, 677: 47-61.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-230X/12/172/prepub
We would like to thank E. Comijn for technical support in animal experiments.
Three of the authors are employees of uniQure (AM, HP and VF), SM currently works in the laboratory of uniQure and SJD is a board member of uniQure.
AM carried out experiments and analyzed the data. AM and VF performed literature searches and wrote the article. SM and AAV participated in the animal experiment, SLM performed histological analysis of colon section, AM, VF, SM, AAV, SLM, HP and SJD contributed conceptually to the work, reviewed the manuscript and assisted with the editing of the paper. All authors read and approved the final manuscript.
About this article
Cite this article
Majowicz, A., van der Marel, S., te Velde, A.A. et al. Murine CD4+CD25- cells activated in vitro with PMA/ionomycin and anti-CD3 acquire regulatory function and ameliorate experimental colitis in vivo . BMC Gastroenterol 12, 172 (2012). https://doi.org/10.1186/1471-230X-12-172
- CD45RB transfer